Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Immuneering Corp (IMRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.37-10.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Extend cash runway to fund operations into 2029 | It aims to fund operations through 2029. | Intact | Cash runs out before end of 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Financial Guidance Based on cash, cash equivalents and marketable securities as of September 30, 2026, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2028.” “Third Quarter 2026 Financial Highlights Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were $166.1 million, compared with $217.0 million as of December 31, 2025.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, meaning its prospects depend heavily on whether its experimental treatment shows benefit. The long-term thesis is in a watch state: trial progress and encouraging Phase 2 evidence are balanced against weak financial performance, ongoing losses, and elevated risk.
The evidence snapshot gives no valuation measure or specific market expectations, so whether IMRX is cheap, fair, or expensive versus peers cannot be assessed. It also reports no valuation fragility flags, but that does not establish what clinical success or failure the market already assumes.
Near term, the company remains loss-making, and higher clinical spending is supporting the expanded Phase 3 trial: third-quarter R&D expense rose versus the same quarter a year earlier. Enrollment is ahead of schedule, but management shortened its cash-runway guidance to the fourth quarter of 2028, and an update on extended Phase 2 follow-up is planned for the first half of 2027.
Over the next one to three years, a key swing factor is whether the Phase 3 MAPKeeper 301 trial advances as planned and whether further data support atebimetinib’s potential benefit. Near-term concerns include a possible guidance cut and weaker employment data, while continued strong results and guidance from healthcare peers could support sector momentum.
The multi-year view remains uncertain: trial progress and reported Phase 2 evidence are meaningful positives, but losses, a shorter stated runway, and pending clinical data keep risk elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance Phase 2a trial of atebimetinib in pancreatic cancer | Immuneering is advancing its pancreatic cancer drug in Phase 2a trials. | Intact | Trial data fails to show efficacy or progress stalls in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Improve earnings toward reducing losses | A supporting condition in Immuneering Corp's published investment case. The stated target is EPS loss narrows from -$1.14 in 2026 to less negative in 2027. | Under Pressure | EPS loss worsens beyond -$1.34 in 2027 | Diluted EPS: $-0.37 per share FY2026-Q3; GAAP. Published target: EPS loss narrows from -$1.14 in 2026 to less negative in 2027. Annual target cannot be compared with a quarterly or TTM observation. Oct 29, 2026-0.37 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.29 → $-1.61 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-25 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-26 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-27 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-28 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-29 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-07-30 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-07-31 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-01 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-08-02 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-03 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-04 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-05 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-06 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-07 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-08 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-09 | $-1.30 | $27,300,000 | 8 / 5 |
| 2026-08-10 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-12 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-13 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-14 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-15 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-16 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-17 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-18 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-19 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-20 | $-1.27 | $17,062,500 | 7 / 8 |
| 2026-08-21 | $-1.27 | $17,062,500 | 7 / 8 |
| 2026-08-22 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-23 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-24 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-25 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-26 | $-1.29 | $19,500,000 | 7 / 8 |
| 2026-08-27 | $-1.29 | $19,500,000 | 7 / 8 |
| 2026-08-28 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-08-29 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-08-30 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-08-31 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-09-01 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-09-02 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-03 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-04 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-05 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-06 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-07 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-08 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-09 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-10 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-11 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-12 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-13 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-14 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-15 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-16 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-17 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-18 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-19 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-20 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-21 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-22 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-23 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-24 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-25 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-26 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-27 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-28 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-29 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-30 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-01 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-02 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-03 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-04 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-05 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-06 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-07 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-08 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-09 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-10 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-11 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-12 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-13 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-14 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-15 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-16 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-17 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-18 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-19 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-20 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-21 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-22 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-23 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-24 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-25 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-26 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-27 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-28 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-29 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-30 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-31 | $-1.55 | $22,750,000 | 6 / 7 |
| 2026-11-01 | $-1.55 | $22,750,000 | 6 / 7 |
| 2026-11-02 | $-1.55 | $22,750,000 | 6 / 7 |
| 2026-11-03 | $-1.55 | $22,750,000 | 6 / 7 |
| 2026-11-04 | $-1.61 | $22,750,000 | 6 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.